Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 1,291 | 159 | 1,128 |
| Samples | 350 | 71 | 278 |
| Peptides | 268 | 50 | 221 |
Function
STAT5A · Signal transducer and activator of transcription 5A
The protein encoded by this gene is a member of the STAT family of transcription factors. In response to cytokines and growth factors, STAT family members are phosphorylated by the receptor associated kinases, and then form homo- or heterodimers that translocate to the cell nucleus where they act as transcription activators. This protein is activated by, and mediates the responses of many cell ligands, such as IL2, IL3, IL7 GM-CSF, erythropoietin, thrombopoietin, and different growth hormones. Activation of this protein in myeloma and lymphoma associated with a TEL/JAK2 gene fusion is independent of cell stimulus and has been shown to be essential for tumorigenesis. The mouse counterpart of this gene is found to induce the expression of BCL2L1/BCL-X(L), which suggests the antiapoptotic function of this gene in cells. Alternatively spliced transcript variants have been found for this gene. [provided by RefSeq, Dec 2013].
Isoforms & Proteins
4 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 249 amino-acid changes on canonical ENST00000590949 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in STAT5A · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in STAT5A – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Chronic Myelogenous Leukemia | 4/25 16% | 0/0 0% |
| T-Lymphoblastic Leukemia | 4/40 10% | 0/0 0% |
| T-Cell Non-Hodgkins Lymphoma | 1/26 4% | 0/0 0% |
| Acute Myeloid Leukemia | 3/90 3% | 0/0 0% |
| Endometrial Carcinoma | 3/42 7% | 13/612 2% |
| Glioblastoma | 2/98 2% | 0/0 0% |
| Oral Cavity Carcinoma | 1/54 2% | 0/0 0% |
| Retinoblastoma | 1/27 4% | 0/30 0% |
| Melanoma | 1/210 0% | 34/1899 2% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 2/133 2% |
| Esophageal Squamous Cell Carcinoma | 0/51 0% | 39/2550 2% |
| Colorectal Carcinoma | 10/143 7% | 37/3239 1% |
| Burkitts Lymphoma | 2/32 6% | 1/196 1% |
| Other Solid Cancers | 2/94 2% | 19/1515 1% |
| Squamous Cell Lung Carcinoma | 2/57 4% | 8/810 1% |
| Neuroendocrine Tumour | 1/154 1% | 6/577 1% |
| Biliary Tract Carcinoma | 0/54 0% | 9/950 1% |
| Cervical Carcinoma | 0/35 0% | 4/422 1% |
| Gastric Carcinoma | 3/74 4% | 13/1809 1% |
| Other Sarcomas | 4/69 6% | 2/699 0% |
| Hodgkins Lymphoma | 1/16 6% | 0/122 0% |
| Non-Small Cell Lung Carcinoma | 6/304 2% | 6/1390 0% |
| Thyroid Gland Carcinoma | 0/45 0% | 11/1592 1% |
| Small Cell Lung Carcinoma | 2/9 22% | 3/752 0% |
| Plasma Cell Myeloma | 2/44 5% | 0/305 0% |
| Head and Neck Carcinoma | 4/85 5% | 5/1574 0% |
| Breast Carcinoma | 3/144 2% | 13/3264 0% |
| Ovarian Carcinoma | 3/109 3% | 2/998 0% |
| Bladder Carcinoma | 0/58 0% | 4/956 0% |
| Esophageal Carcinoma | 0/23 0% | 3/769 0% |
Mutation Distribution
Where STAT5A is mutated · all tissues, split by cell line vs tissue
How many mutations in STAT5A were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 1,291 mutations in STAT5A
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|